| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 874.0 | 860.5 |
| Gross profit | 429.3 | 379.4 |
| Profit before tax | -120.3 | -71.8 |
| Net income | -111.8 | -59.6 |
| EPS (diluted, $ a share) | $-0.81 | $-0.41 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +1.6% |
|---|---|
| Gross margin | 49.1% |
| Operating margin | -10.4% |
10-Q filed with the SEC, NASDAQ: BRKR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Bruker Corp: key numbers
- Share price
- $60.62Close, Nov 16
- Sector
- Industrial Applications and Services
- Industry
- Laboratory Analytical InstrumentsSIC 3826
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Bruker Corp
All →Bruker Leadership Change
Bruker Corporation has appointed Dr. Eicke Latz to its Board of Directors, effective January 1, 2027, expanding the board to twelve members. Dr. Latz is a physician-scientist and biopharma entrepreneur who currently serves as the Scientific Director of the German Rheumatology Research Center. Additionally, the Board declared a quarterly cash dividend of $0.05 per share payable on January 7, 2027.
Bruker Business Update
Bruker Corporation completed a reorganization of its reportable segments to streamline its organizational structure, effective July 1, 2026. The company recast its historical segment financial information for 2024, 2025, and 2026 to conform to the new structure, which now includes BSI BIOS and BSI Microbiology and Infection Diagnostics (BMID).
Bruker Financial Results
Bruker Corp reported Q3 2026 revenue of $874.0 million, a 1.6% increase year-over-year, and a non-GAAP operating margin expansion of 400 basis points to 16.3%. Despite a GAAP diluted loss per share of $(0.81) due to non-cash goodwill impairment charges, non-GAAP diluted EPS grew 24.4% to $0.56. The company reconfirmed its full-year 2026 organic revenue growth and non-GAAP EPS guidance.
- Term
- Q3 2026
“Bruker drives significant advances in post-genomic drug discovery and disease biology research, from proteoforms to glycobiology, and from functional protein interactions to spatial biology. These deeper insights into molecular, cell and tissue biology are foundational for successful drug development and useful AI frontier models. Together with strong growth-drivers in infectious disease diagnostics, and in deep-tech and semiconductor metrology, we are poised for growth acceleration.”
Frank H. Laukien, Bruker’s President and CEO
“In the third quarter, we achieved very significant margin expansion and non-GAAP EPS growth, driven by our focus on cost discipline and execution. Bruker’s positive booking trends continued with the fifth consecutive quarter of Bruker Scientific Instruments (BSI) book-to-bill greater than one. We see strengthening demand in most of our end markets, and in Q3 also in the US academic market. With BSI organic bookings and backlog both up mid-single digits % year-to-date, we expect revenue growth acceleration, continued margin expansion and double-digit EPS growth in FY27.”
Frank H. Laukien, Bruker’s President and CEO
Bruker Dividend
Bruker Corporation's Board of Directors declared a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A. The dividend is payable on December 1, 2026, to shareholders of record as of November 15, 2026.
Bruker Exec Vp&Pres Bruker Nano Inc. Mark Munch Sells $106K of Stock
Mark Munch, Exec Vp&Pres Bruker Nano Inc., sold 2,000 shares of Bruker Corp at $52.87 a share, worth $106K in total on Sep 15, 2026. Shares held after the trade: 134,806 (-1.5%).
- Value
- $106K
- Shares
- 2,000
- Price
- $52.87
- Role
- Exec Vp&Pres Bruker Nano Inc.
- Holding change
- -1.5%
- Trade date
- Sep 15, 2026